CS
FHTX icon

Candriam SCA’s Foghorn Therapeutics FHTX Stock Holding History

Candriam SCA’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.5M Buy
+313,765
New +$1.72M 0.01% 562

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Candriam SCA's FHTX Position: Q1 2026 in Review

Candriam SCA opened a new position in Foghorn Therapeutics (FHTX) in Q1 2026: 313,765 shares worth $1.5M. The stake represents 0.01% of the portfolio and ranks #562 among its holdings.

105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Candriam SCA held 313,765 shares of Foghorn Therapeutics worth $1.5M as of Q1 2026.
  • Foghorn Therapeutics was a new Candriam SCA position in Q1 2026.
  • Foghorn Therapeutics made up 0.01% of Candriam SCA's portfolio in Q1 2026, its #562 holding.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.